Monitor the PTAB docket for the final written decision, expected within about 12 months. The outcome could affect Neurocrine's competitive positioning in adrenal rest tumor therapies if the patent covers a product or method relevant to its pipeline.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $169.14entry
- T+1 · 6d ago +3.12%α +1.80% · $174.41
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outExecutive Summary
The PTAB granted institution of a post-grant review (PGR2026-00060) on Neurocrine Biosciences' challenge to Spruce Biosciences' U.S. Patent 12,569,490 covering methods for treating testicular and ovarian adrenal rest tumors. The decision is interlocutory, no claims have been cancelled, and the trial will proceed on the merits.
PTAB Trial Details
Key Facts
- PTAB granted institution of PGR2026-00060 on November 10, 2026
- Patent U.S. 12,569,490 covers methods for treating testicular and ovarian adrenal rest tumors
- Neurocrine Biosciences is the petitioner; Spruce Biosciences is the patent owner
- The decision is interlocutory, no claims have been cancelled or held unpatentable
- A final written decision is due within approximately one year
Financial Impact
Not stated in the decision; the patent's revenue exposure for either party is not quantified
Risk Factors
- Institution is interlocutory; no claims have been invalidated
- The patent's materiality to Neurocrine's revenue or pipeline is not stated in the decision
- A final written decision may be appealed to the Federal Circuit
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 PTAB decision.
| Document | Accession Number |
|---|---|
| PTAB-TRIAL Data (Synthetic) | ptab-PGR2026-00060-ins-NBIX |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Viewing Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time PTAB Decision Intelligence
Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers